Business Wire

Neovii Pharmaceuticals AG Establishes Global Scientific Department

Jaa

Neovii continues to strengthen its leadership team and capabilities with the appointment of Richard Sachse as Global Chief Scientific Officer. With the appointment of Dr. Sachse, Neovii has set up a Global Scientific Department which comprises all regulatory, medical, and development activities globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180703005142/en/

Richard Sachse, Global Chief Scientific Officer, Neovii (Photo: Business Wire)

Richard Sachse, Global Chief Scientific Officer, Neovii (Photo: Business Wire)

Neovii’s CEO Juergen Pohle commented: “By establishing a Global Scientific Department, Neovii makes another step forward to become a leading biopharmaceutical company in the transplantation segment.” He added: “We are very excited that Richard joins Neovii and will establish the new Global Scientific Department. His deep understanding and long-term experience in clinical development and regulatory activities, as well as his know-how and strong leadership skills, make him the right person to push this role forward and to drive the business into our next chapter.” Dr. Sachse will also join Neovii’s Global Leadership Team.

Dr. Sachse previously held the position of Senior Vice President, Chief Scientific Officer, and Chief Medical Officer at Æterna Zentaris. In this role Dr. Sachse succeeded in designing and completing development programs for FDA drug approval. He draws on more than 20 years of experience in the pharmaceutical industry not only at Æterna Zentaris, but also with Boehringer Ingelheim, UCB, Schwarz Biosciences, Peptor, and Bayer.

Richard Sachse pointed out: “I am excited to join Neovii and to build the new Global Scientific Department comprising regulatory, medical, and development activities. Driving Neovii to become a full-fledged pharmaceutical company is a challenging but rewarding task, and I am certain that my previous experience will highly benefit Neovii. I am enthusiastic to begin working with our in-licensing partners to provide better paths to key markets for the most innovative lines of treatments in transplantation and rare diseases.”

Neovii also appointed former Pfizer executive Alfred Doucette as Global CFO at the beginning of the year. Alfred Doucette has held several senior finance positions within Pfizer and was most recently the Commercial Director for Pfizer Consumer Healthcare for the SEE/CIS/Baltics/Greece & Cyprus, Israel and Turkey regions, bringing a huge wealth of experience in financial management.

About Neovii

Neovii is an independent, dynamic, rapidly-growing and global biopharmaceutical company with a patient-focused mission to develop and market novel life-transforming therapies.

Neovii has been dedicated for over three decades to improving the outcomes in transplantation medicine and the treatment options for hemato-oncological as well as immune disorders.

Neovii Pharmaceuticals AG’s global headquarters is located in Rapperswil, Switzerland and has a branch office in Lexingtion MA, USA. Its biotechnology manufacturing facility is in Graefelfing, Germany. Neovii’s products are available in over 50 countries worldwide.

For further information

For further information, please visit www.neovii.com.

Contact information

For Neovii Pharmaceuticals AG
Daniela Suter, 0041 (0)44 455 84 25
daniela.suter@bm.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

In Preparation for the 2019 Proxy Season, CGLytics Expands Global Coverage and Appoints New Head of Research20.2.2019 22:10:00Tiedote

In recent years, increased shareholder activism and an overall heightened awareness of companies’ governance practices, has led to the need for greater transparency of exposure to governance and reputational risks. CGLytics, a leading corporate governance analytics provider, is continuing to drive transparency of good governance practices for better informed decision-making, by expanding its global coverage. Part of the expanded global coverage for its powerful, cloud-based governance platform includes an increase of company data from 3,300 to 5,500 listed companies across North America, Europe and Australia. This increase provides companies and investors with the deepest global governance data set in the market to date. For Investors, this increase in coverage will permit a substantially broader reach when analysing the potential governance risk in their portfolios, allowing for better engagement, decision-making and stewardship. Moreover, Issuers will gain a more in-depth capacity to

Payments Canada Selects SIA As the Application Provider for Canada’s New High-Value Payments System, Lynx20.2.2019 18:30:00Tiedote

Payments Canada announced today the selection of SIA as the application provider for the country’s new high-value payments system, Lynx. This payments Modernization milestone is the outcome of an extensive procurement process with participation from key industry partners, including Canadian financial institutions. In April 2017, Payments Canada announced a list of suppliers invited to participate in a competitive procurement process for Lynx. This process has ended, and Payments Canada has selected SIA as the Lynx application provider, subject to negotiation of the final agreement and final regulatory approval. SIA will work closely with Payments Canada and key industry stakeholders on the next version of their Real-Time Gross Settlement (RTGS) application solution to deliver on the needs identified during consultations for the future of payments in Canada, in compliance with strict Canadian and international risk standards. SIA is well known in the global landscape as a leader in paym

Arch Capital Group Ltd. Names Janice Englesbe Senior Vice President, Chief Risk Officer20.2.2019 18:10:00Tiedote

Arch Capital Group Ltd. (“Arch”) today announced that Janice Englesbe will join the Company as Senior Vice President, Chief Risk Officer (CRO) effective February 25, 2019. Ms. Englesbe will be based in Arch’s Bermuda office and report to François Morin, the Company’s Executive Vice President and Chief Financial Officer. As CRO, Ms. Englesbe will have overall responsibility for the Company’s risk management function. Additionally, she will help formulate and implement business strategies and provide comprehensive counsel to the executive leaders and board members. “Janice brings a wealth of experience and demonstrated ability to implement practical results,” Mr. Morin said. “I’m looking forward to the unique perspective and leadership she will bring to Arch.” Ms. Englesbe has over 25 years of risk and finance experience, including Group Deputy Chief Risk Officer of General Re, and has been named one of Intelligent Insurer’s 100 Influential Women in Re/insurance. She holds a bachelor’s d

Ingram Micro and MassChallenge Name Comet Competition Top B2B Startups20.2.2019 18:00:00Tiedote

Ingram Micro Inc., in partnership with MassChallenge, today announced the top 12 finalists from its Tel Aviv, Austin, and Boston Comet Competition s. The finalists for this year’s inaugural competition are Verifyoo, Perimeter 81, ITsMine, EyeControl, ClearBlade, re:3D, Sempulse, The Mentor Method, Pixm Inc., addapptation, OnRout, and BOXOLOGIC.COM. Established in 2018, the Comet Competition is the only startup challenge dedicated to discovering talented B2B independent software vendors (ISVs) and accelerating their trajectory to channel market success. As Comet Competition finalists, these startups will receive go-to-market funding, unparalleled access to top corporate partners, and tailored curriculum to accelerate their success – all for zero equity. “In order to continue to be a leader in the digital economy, we need to actively search for the world’s best technology startups and catapult their trajectory to profitability and scale,” says Nimesh Davé, executive vice president, Ingra

KCI Launches ABTHERA™ Therapy in Japan20.2.2019 17:30:00Tiedote

KCI, an Acelity Company, today announced the launch of ABTHERA™ Open Abdomen Negative Pressure Therapy in Japan, expanding access to the Company’s surgical portfolio in the country. ABTHERA™ Therapy is a temporary abdominal closure system that allows surgeons to take control in managing challenging abdominal wall openings where primary closure is not possible and/or repeat abdominal entries are necessary. “When dealing with patients managed with damage control for severe abdominal hemorrhage, abdominal compartment syndrome or severe peritonitis, using ABTHERA™ Therapy has been shown to be associated with proven patient outcomes,” said Dr. Demetrios Demetriades, Professor of Surgery, Keck USC School of Medicine and the Director of the USC Division of Trauma, Emergency Surgery and Surgical Intensive Care Unit. “With the introduction of ABTHERA™ Therapy in Japan, clinicians now have a clinically demonstrated solution for a previously unmet, significant need, that manages the open abdomen

ResMed and Fisher & Paykel Healthcare Announce Settlement of Global Patent Infringement Litigation20.2.2019 17:00:00Tiedote

ResMed (NYSE: RMD, ASX: RMD), and Fisher & Paykel Healthcare (NZX: FPH, ASX: FPH) today announced an agreement to settle all outstanding patent infringement disputes between the companies in all venues around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190220005556/en/ The settlement involves no payment or admission of liability by either side. Under the agreement, all ongoing infringement proceedings against named products will be dismissed, and each party will bear its own attorney fees and costs incurred in the global proceedings. All other terms remain confidential. As a result of the settlement, there will be no further infringement proceedings against ResMed products, including AirSense flow generators, AirFit P10, Swift LT and Swift FX masks, and ClimateLine heated tubes; or against Fisher & Paykel Healthcare products including Simplus, Eson and Eson 2. “I am pleased we were able to resolve these dispute

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme